Skin care and side effects prevention methods during Tepotinib (Tuodekang) treatment

Tepotinib is a selective MET inhibitor that is widely used to treat patients with non-small cell lung cancer with MET exon 14 skipping mutations. During clinical use, some patients may experience skin-related side effects, such as rash, dryness, itching or mild erythema. Although these symptoms are usually mild to moderate, if not cared for, they may affect the patient's quality of life and indirectly affect treatment compliance.

During treatment, patients should keep their skin clean and moist. It is recommended to use mild, fragrance-free cleaning products for bathing and avoid frequent use of alkaline or irritating soaps. Apply moisturizing lotion or cream promptly after bathing, paying special attention to hands, feet, face and dry areas to reduce skin dryness and itching. In addition, avoid prolonged exposure to the sun and use sunscreen and sun-shade clothing when necessary to reduce skin irritation from ultraviolet rays.

For patients who have mild rash or itching, they can use local low-intensity corticosteroid cream or antihistamines under the guidance of a doctor for symptomatic treatment. At the same time, avoid scratching or using harsh skin care products to prevent secondary infection. Some patients can use preventive skin care regimens according to medical advice in the early stages of treatment, such as daily gentle moisturizing, avoiding hot water scalding, and moderate moisturizing, which can help reduce the risk of rashes and dryness.

During treatment with tepotinib, patients should be followed up regularly and report skin changes. If moderate or severe rash, ulcer, infection or significant itching occurs, the doctor may adjust the dose or temporarily stop the drug, combined with professional dermatology treatment. Through the combination of daily care and timely intervention, most skin side effects are controllable and reversible, while ensuring that patients successfully complete treatment and improving overall efficacy and quality of life.

Reference materials:https://www.drugs.com/